Jump to:

PHARMASEAL International Ltd hero image

PHARMASEAL International Ltd

Follow

Flexible & adaptive trial solutions provider.

118%
 - 
Funded 22 May 2023
£450,000 target
£535,122 from 206 investors
More
Less

Business overview

Location Nottingham, United Kingdom
Social media
Website www.pharmaseal.co
Sectors Healthcare Mixed Digital/Non-Digital B2B
Company number 09993255
Incorporation date 8 Feb 2016
More
Less

Investment summary

Type Equity
Valuation (pre-money) £5M
Equity offered 9.59%
Tax relief

EIS

More
Less

Business highlights

  • Pharmaseal ARR exceeds £400k*
  • 10 Biopharmaceutical & Medical Device Customers Signed
  • 17 Software Releases Delivered, 2023 Major Release Scheduled Q1
  • 1st Commercial Reseller Partnership with Medrio (USA) Signed
More
Less

Key features

  • Secondary Market
  • Nominee investment min. £18.00 +
  • Direct investment min. £25,000.00 +

Idea

Introduction

Pharmaseal is a software company that aims to disrupt clinical trial management with its Engility® B2B platform, ensuring compliance with international good clinical practice (GCP) requirements. Clinical trials involve thousands of patients and take 1-5 years to complete, and are a crucial step in licensing new prescription drugs/devices.

Engility® unifies separate applications into a single platform, ensuring GCP compliance, centralizing information, removing data duplication, and making enterprise systems more affordable for SME companies. Almost 50% of clinical trials are outsourced to CROs (suppliers).

Engility® enables companies and their suppliers to share the same system, enhancing collaboration on clinical trial projects and improving overall governance across the supply chain, join Pharmaseal in transforming the effectiveness of clinical trial management.

* Based on unaudited management accounts.

Substantial accomplishments to date

2019: H1: Second seed round closed raising £1m+

2019: H1: Initial Release of Engility® with the first foundation product, Clinical Trial Management System (CTMS)

2019: H2: First customer signed a 3-year subscription to Engility®

2019: H2: Pharmaseal wins East Midlands "Start-Up Company of the Year"

2020: H1: Initial Release of the second product, electronic trial master file (eTMF), which unifies clinical process management and document management in a single cloud platform

2020: H2: Pharmaseal wins £100k Innovate UK grant for a research project

2020: H2: Interim funding round closed (£500k) with Seedrs and HNI's to support operational cashflow and impact of Covid on clinical trials

2021: H1: Medrio (USA) and Pharmaseal signed a strategic reseller agreement, allowing Medrio to sell Engility® to its customers. Engility® complements the use of Medrio's data management products

2022: H2: Pharmaseal and Medrio commit R&D resources to develop an integration between Medrio EDC Data Management and Engility® Trial Management platforms

2022: H2: Pharmaseal acquires 10 global customers

2022: H2: Pharmaseal completes a successful onsite audit by a top-20 Pharmaceutical company

2022: H2: First customer renews for another 3-year subscription license of Engility®

2023: H1: Pharmaseal attends and exhibits at first trade conference (Clinical Outsourcing Group) in London since the pandemic

2023: H1: Pharmaseal ARR exceeds £400k with 11 customers and initates interim funding round*

* Based on unaudited management accounts for the year 1st April 2022 - 2 March 2023.

Monetisation strategy

The Engility® platform is licensed as a SaaS product. It is offered in two product combinations:

Engility® Standard: With a single product - Clinical Trial Management System (CTMS) which supports clinical process management of Good Clinical Practice (GCP)

Engility® Enterprise: With both CTMS and an electronic trial master file (eTMF - document management) in a unified platform.

The subscription contract duration is either for a committed volume of clinical trials on a typical 3-year (perpetual) volume licensing deal or for the specific duration of one or more clinical trials (project duration).

The flexible licensing approach caters for companies who have different demands for trials, based on their size, maturity and product lifecycles.

As enterprise-wide information, Engility® becomes the repository of all clinical trials conducted by an organisation and/or a supplier and hence the "execution record" of conduct. This makes Engility a "sticky" enterprise system with long-term usage.

Use of proceeds

The interim round is expected to support a minimum of 12 months of operating cash flow as the company is already generating £400k+ ARR*. The investment will support additional commercialisation and marketing expenditure and additional engineering resources for product development.

The company will attend and aims to exhibit at additional trade shows during 2023 targeting USA and Europe with suitable events.

Growth through channel partnerships will require dedicated resources to manage the channels, and a commercial director will be hired to support existing management.

Additional product development to support the integration of Engility® with other 3rd party products will be accelerated over the next 12 months. We expect this to increase sales sourced from channel partners.

The company aims to add 10 more customers in the fiscal year April 2023-March 2024, and we hope to be able reach both a breakeven position, and sufficient revenue to commence planning for a Series A round, in the latter half of 2024.

Key Information

Debt

The company has the following outstanding loans:

£50,000 bounce-back loan from HSBC at an interest rate of 2.5% per annum. The loan is to be repaid on 20-07-2030.

The funds raised from this investment round will not be used to repay these loans.

Open an account to get access to the team members of PHARMASEAL International Ltd

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for PHARMASEAL International Ltd has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 6 April 2023 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £5,039,541

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Nominee investment

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Nominee investment.

Find out more

Custodian

If you invest in this Campaign, Seedrs will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Seedrs will not benefit from any rights under a shareholder agreement. As a result, Seedrs will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

This is an option to invest and hold shares 'directly' in the company (rather than via the Nominee investment). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Seedrs. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Security Token

A security token is a digital asset that represents ownership or other rights. It is a digital form of traditional investments. In the future, you may be able to trade your investment through compatible exchanges.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel